申请人:Akzo Nobel N.V.
公开号:EP0887349A1
公开(公告)日:1998-12-30
The present invention relates to certain tetrahydroimidazo[2,1-a]isoquinoline derivatives according to formula I
wherein X is a group (A) or (B)
R1, R2 and R3, which may be the same or different, each represent one or more substituents selected from hydrogen, C1-6alkyl, C3-6cycloalkyl C1-6alkoxy, C1-6alkylthio, C4-6cycloalkenyl, C2-6alkenyl, C2-6alkynyl and halogen; R4, R5, R6 and R7, which may be the same or different, are each selected from hydrogen, C1-6alkoxyC1-6alkyl, C4-6cycloalkenyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl and C1-6alkyl; n is 1 or 2; or a pharmaceutically acceptable salt or solvate thereof, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of depression.
本发明涉及某些符合式 I 的四氢咪唑并[2,1-a]异喹啉衍生物
其中 X 是基团 (A) 或 (B)
R1、R2 和 R3 可以相同或不同,各自代表一个或多个取代基,选自氢、C1-6 烷基、C3-6 环烷基 C1-6烷氧基、C1-6烷硫基、C4-6 环烯基、C2-6烯基、C2-6炔基和卤素;R4、R5、R6 和 R7 可以相同或不同,各自选自氢、C1-6烷氧基 C1-6烷基、C4-6 环烯基、C2-6烯基、C2-6炔基、C3-6 环烷基和 C1-6烷基;n为1或2;或其药学上可接受的盐或溶液,以及制备它们的工艺、含有它们的药物制剂和它们在医疗中的用途,特别是在治疗抑郁症中的用途。